Long-term survival analysis of the DESTINY-Breast03 trial reveals the efficacy of Trastuzumab Deruxtecan versus Trastuzumab Emtansine in HER2-positive metastatic breast cancer. Explore more about the findings in this Nature Medicine article: https://lnkd.in/dRCDS9Qu #ASCO24 #BreastCancer #CancerResearch #Oncology #Immunotherapy #ClinicalTrials #MedicalResearch
Sarah Cannon Research Institute
Research Services
Nashville, TN 14,182 followers
A leading oncology research organization conducting community-based clinical trials.
About us
Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. In 2022, SCRI formed a joint venture with former US Oncology Research to expand clinical trial access across the country. It has conducted more than 750 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA today. SCRI’s research network brings together more than 1,300 physicians who are actively enrolling patients into clinical trials at more than 250 locations in 24 states across the U.S.
- Website
-
https://www.scri.com
External link for Sarah Cannon Research Institute
- Industry
- Research Services
- Company size
- 501-1,000 employees
- Headquarters
- Nashville, TN
- Type
- Privately Held
- Founded
- 1993
- Specialties
- Oncology and Cancer Research
Locations
-
Primary
Get directions
1100 Charlotte Avenue
Nashville, TN 37203, US
Employees at Sarah Cannon Research Institute
Updates
-
David R. Spigel, MD's presentation at ASCO highlighted lung cancer treatment findings, earning a standing ovation. Read more in this Fierce Pharma article: https://lnkd.in/eyBPWbhu #ASCO24 #LungCancer #CancerResearch #Oncology #Immunotherapy #MedicalInnovation
ASCO: AstraZeneca's Tagrisso, Imfinzi break new ground in lung cancer—with one standing ovation
fiercepharma.com
-
Dr. Meredith McKean presented results from pivotal melanoma trials at #ASCO24, including KEYMAKER-U02A, IMC-F106, and SC-682. Discover the latest advancements in melanoma treatment in this Video Journal of Oncology (VJOncology) video: https://lnkd.in/gXfdrdmj #ASCO24 #Melanoma #CancerResearch #Oncology #Immunotherapy #ClinicalTrials
Melanoma trials at ASCO 2024: KEYMAKER-U02A, IMC-F106 and SC-682 - VJOncology
https://www.vjoncology.com
-
Cesar Perez M.D., SCRI’s Executive Chair of the Head & Neck Cancer Research Executive Committee, and Director of Drug Development for SCRI at Florida Cancer Specialists & Research Institute (FCS) – Lake Nona; shares his insights on the various innovations to come for head and neck cancers in recognition of Cancer Immunotherapy Month. Read his article below to discover his insights for the future of cancer care for those impacted by head and neck cancers and other immune-related cancers. #Oncology #Innovation #CancerImmunotherapyMonth #Immunotherapy #LifeatFCS #40Forward
Sarah Cannon Research Institute at Florida Cancer Specialists | Florida Cancer Specialists & Research Institute
I became a doctor knowing it would allow me to have a real impact on others. In observance of Cancer Immunotherapy Month, my hope for all patients facing a cancer diagnosis is a future where, even more than today, cancer can be confronted with not just hope but with new tangible, effective treatment options. Read my article below to learn more and discover how together, with the Sarah Cannon Research Institute and Florida Cancer Specialists & Research Institute (FCS), we are advancing oncology care. #Oncology #Innovation #CancerImmunotherapyMonth #Immunotherapy
Increasing the Impact of Immunotherapy
Cesar Perez M.D. on LinkedIn
-
Exciting developments in cancer treatment! Erika Hamilton, MD, discusses the potential of 'smart warheads' in oncology. Learn about the innovative approaches in this Becker’s Hospital Review article: https://lnkd.in/g7z3MQtq #ASCO24 #CancerResearch #Oncology #InnovativeTreatment #Immunotherapy #MedicalResearch
'Smart warheads' of cancer: Experts' excitement for treatment approach grows
beckershospitalreview.com
-
Significant advancements in NSCLC treatment! SCRI's Dr. Robert Jotte presents how Adagrasib shows improvement in PFS and ORR over Docetaxel in previously treated patients. Watch his detailed discussion on ecancer: https://lnkd.in/ghE9E4XP #ASCO24 #NSCLC #CancerResearch #Oncology #Immunotherapy #ClinicalTrials
Adagrasib improves on docetaxel in previously treated NSCLC - ecancer
ecancer.org
-
Join Dr. Meredith McKean in exploring the potential of JZP898, an IFN-α, and Pembrolizumab in treating advanced solid tumors. Watch her detailed evaluation on Video Journal of Oncology (VJOncology): https://lnkd.in/gzjRxJY7 #ASCO24 #CancerResearch #Oncology #Immunotherapy #SolidTumors #MedicalResearch
Evaluating JZP898, an IFN-α and pembrolizumab in advanced solid tumors - VJOncology
https://www.vjoncology.com
-
David R. Spigel, MD, recently presented results from the ADRIATIC study on limited-stage small cell lung cancer. Discover the implications for patient care in this video from The American Society of Clinical Oncology (ASCO) Post: https:/https://lnkd.in/evPni2rc #ASCO24 #LungCancer #CancerResearch #Oncology
Narjust Florez, MD, and David R. Spigel, MD, on Limited-Stage Small Cell Lung Cancer: Results From the ADRIATIC Study
ascopost.com
-
David R. Spigel, MD discusses how immunotherapy extends survival for patients with a rarer type of lung cancer. Read more about these significant findings in Bio Pharma Dive: https://lnkd.in/gFevCAzN #lungcancer #OncologyAdvancements
AstraZeneca immunotherapy extends survival by two years in rarer type of lung cancer
biopharmadive.com
-
Chief Scientific Officer for SCRI, David R. Spigel, MD, shares exciting lung cancer therapy updates with Yahoo News: https://lnkd.in/eEN2PPSQ
Incurable lung cancer could be ‘stopped in its tracks’ by new pill
yahoo.com